1. Home
  2. DSGN vs DERM Comparison

DSGN vs DERM Comparison

Compare DSGN & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • DERM
  • Stock Information
  • Founded
  • DSGN 2017
  • DERM 2014
  • Country
  • DSGN United States
  • DERM United States
  • Employees
  • DSGN N/A
  • DERM N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • DERM Biotechnology: Pharmaceutical Preparations
  • Sector
  • DSGN Health Care
  • DERM Health Care
  • Exchange
  • DSGN Nasdaq
  • DERM Nasdaq
  • Market Cap
  • DSGN 208.9M
  • DERM 190.7M
  • IPO Year
  • DSGN 2021
  • DERM 2021
  • Fundamental
  • Price
  • DSGN $5.74
  • DERM $7.20
  • Analyst Decision
  • DSGN
  • DERM Strong Buy
  • Analyst Count
  • DSGN 0
  • DERM 3
  • Target Price
  • DSGN N/A
  • DERM $12.67
  • AVG Volume (30 Days)
  • DSGN 201.9K
  • DERM 115.5K
  • Earning Date
  • DSGN 11-06-2025
  • DERM 11-11-2025
  • Dividend Yield
  • DSGN N/A
  • DERM N/A
  • EPS Growth
  • DSGN N/A
  • DERM N/A
  • EPS
  • DSGN N/A
  • DERM N/A
  • Revenue
  • DSGN N/A
  • DERM $56,397,000.00
  • Revenue This Year
  • DSGN N/A
  • DERM $26.16
  • Revenue Next Year
  • DSGN N/A
  • DERM $45.27
  • P/E Ratio
  • DSGN N/A
  • DERM N/A
  • Revenue Growth
  • DSGN N/A
  • DERM N/A
  • 52 Week Low
  • DSGN $2.60
  • DERM $3.54
  • 52 Week High
  • DSGN $7.77
  • DERM $8.90
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 43.44
  • DERM 47.87
  • Support Level
  • DSGN $6.01
  • DERM $6.91
  • Resistance Level
  • DSGN $7.21
  • DERM $7.72
  • Average True Range (ATR)
  • DSGN 0.62
  • DERM 0.34
  • MACD
  • DSGN -0.12
  • DERM -0.00
  • Stochastic Oscillator
  • DSGN 3.65
  • DERM 31.02

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Share on Social Networks: